With the market for juvenile ADHD plateauing at 4.5 million children, pharmaceuticals are looking to the untapped “immature” adult market. With criteria such as “often fails to give close attention to details”, difficulty in “sustaining attention”, failing to follow through on instructions, difficulty organizing tasks, losing things, being easily distracted, or forgetful, the potential market is estimated to be twice as large as it is in children.
So… young people who are bored at work because because they are underemployed are a new potential market. When I read about any psychiatrist that is interested/specializes in adult ADHD I know that that person is really just in it for the “market” share.
Report comment
Just more quackery from the marriage between psychiatry and Big Pharma!
Report comment